Page 113 - MemoriaBBN-Eng

www.ciber-bbn.es

• Pharmacocinetic and biopharmaceutical evaluation of modified drug delivery and

therapeutic systems obtained with bio technologic products.

• NANOCARRIERS FOR PULMONARY ADMINISTRATION: the aim of this work line is the

design, optimization and characterization of vehicles in the nanometric range that
are intended to be administered pulmonary. These systems present many ad-

vantages, such as mucoadhesion, biodegradability, no first pass effect hence the
possibility to reduce the dose, good tolerability, deep lung deposition of the drug

and sustained release of the API thus longer dosing interval. These systems are

applied for the nanoformulation of DNA, peptide, antineoplasics and antibiotics.

Most relevant • sAntos e, lArzABAl l, CAlvo A, orive G, PedrAz Jl, hernández rm.. Inactivation of encap-
sulated cells and their therapeutic effects by means of TGL triple-fusion reporter/
scientific
biosafety gene.BIOMATERIALS. 2013;34(4):1442-51.
articles
• sAntos e, PedrAzJl, hernández rm, orive G.. Therapeutic cell encapsulation: ten steps

towards clinical translation.Journal Controlled Release. 2013;:1-14.

• herrAn e, Pérez-González r, iGArtuA m, PedrAz Jl, CArro e, hernández rm.. VEGF-relea-
sing biodegradable nanospheres administered by craniotomy: a novel therapeutic

approach in the APP/Ps1 mouse model of Alzheimer’s disease.Journal of Controlled
Release. 2013;170(1):111-9.

• o G, s e, P Jl, h rm.. Application of cell encapsulation for con-
riveAntosedrAzernándezá
trolled delivery of biological therapeutics.Advanced Drug Delivery Reviews. 2014;.

• del BurGo ls, hernndez rm, orive G, PedrAz Jl.. Nanotherapeutic approaches for bra-

in cancer management.Nanomedicine. 2014;.

Highlights
During 2013 year, we have obtained 4 new SAIOTEK projects from the ¨Departa-
mento de Industria y Comercio del Gobierno Vasco¨, in different research areas

such as: New strategies to transfect efficiently neurons with non-viral vectors;

Delivering of neurotrophic factors to the brain for the treatment of Parkinson
diseases; Cell containing scaffolds for bone regeneration and technologies for

peptides purification.

Two patents have been developed for the Praxis Pharmaceutical S.A Company:

“Lipidic nanoparticles for wound cicatrisation” and “Polymyxin containing lipidic
nanoparticles”.

The following patent has been developed in collaboration with the CIBERER, UAM,

and the CSIC: “Biodegradable nanoparticles for the GSE24-2 peptide release,
extraction and use procedure”.

Two research members of our team had the opportunity to further develop their

research skills in England (Bath University) and Germany (Institute for Biological
13
and Medical Imaging (IBMI), Helmholtz Centre in Munich).
20
T
Three doctoral thesis were defended during 2013 year: “Optimization of cell mi- OR
croencapsulation in terms of biosafety, biomimesis and applicability in therapeutic P
RE
targets of central nervous system”, Microparticlulate systems as adjuvants of anti L
malaria synthetic antigens” and “Gastro-resistant microparticles as an oral chole- A
NU
ra vaccine approach”.
N
A
In 2013, 14 new articles and three book chapters have been published “Immobi- N /
B
lization of Enzymes and Cells”. Book chapters are:
-B
R
“Biomedical Applications of Immobilized Enzymes: An update, Encapsulation of BE
Cells in Alginate Gels” and “Therapeutic Applications of Encapsulated Cells”.
CI

113